遗传性共济失调(HA)是一组罕见的异质性疾病。这里,我们使用定制设计的下一代测序(NGS)小组对一组共济失调患者进行分子检测.由于遗传性共济失调和痉挛性截瘫(HSP)的遗传和临床重叠,该组包括HA和HSP基因。NGS图书馆,包含152个基因的编码序列,使用KAPAHyperPlus和HyperCap靶标富集试剂盒进行,在MiSeq仪器上测序。使用BaseSpace变体解释器和整合基因组学查看器分析结果。使用Sanger测序确认所有致病性和可能的致病性变体。共有29例遗传性共济失调患者参加了NGS检测,16例患者分子诊断确诊,诊断准确率为55.2%。在10个不同的基因中鉴定出致病性或可能的致病性突变:POLG(PEOA1,n=3;SCAE,n=2),CACNA1A(EA2,n=2),SACS(ARSACS,n=2),SLC33A1(SPG42,n=2),STUB1(SCA48,n=1),SPTBN2(SCA5,n=1),TGM6(SCA35,n=1),SETX(AOA2,n=1),ANO10(SCAR10,n=1),和SPAST(SPG4,n=1)。我们证明,基于NGS面板的靶向使用的方法可以是非常有效的,并且是共济失调患者分子诊断的有用工具。此外,我们强调,针对共济失调和HSP基因的测序组提高了诊断成功率.
Hereditary ataxias (HA) are a rare group of heterogeneous disorders. Here, we present the results of molecular testing of a group of ataxia patients using a custom-designed next-generation sequencing (NGS) panel. Due to the genetic and clinical overlapping of hereditary ataxias and spastic paraplegias (HSP), the panel encompasses together HA and HSP genes. The NGS libraries, comprising coding sequences for 152 genes, were performed using KAPA HyperPlus and HyperCap Target Enrichment Kit, sequenced on the MiSeq instrument. The results were analyzed using the BaseSpace Variant Interpreter and Integrative Genomics Viewer. All pathogenic and likely pathogenic variants were confirmed using Sanger sequencing. A total of 29 patients with hereditary ataxias were enrolled in the NGS testing, and 16 patients had a confirmed molecular diagnosis with diagnostic accuracy rate of 55.2%. Pathogenic or likely pathogenic mutations were identified in 10 different genes: POLG (PEOA1, n = 3; SCAE, n = 2), CACNA1A (EA2, n = 2), SACS (ARSACS, n = 2), SLC33A1 (SPG42, n = 2), STUB1 (SCA48, n = 1), SPTBN2 (SCA5, n = 1), TGM6 (SCA35, n = 1), SETX (AOA2, n = 1), ANO10 (SCAR10, n = 1), and SPAST (SPG4, n = 1). We demonstrated that an approach based on the targeted use of the NGS panel can be highly effective and a useful tool in the molecular diagnosis of ataxia patients. Furthermore, we highlight the fact that a sequencing panel targeting both ataxias and HSP genes increases the diagnostic success level.